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Abstract. During the last years, our emphasis has focused in the 
study of the neurotoxic effects of 3,4-
methylenedioxymethamphetamine (MDMA) and methamphetamine 
(METH) on central nervous system and their pharmacological 
prevention. In the process of this research, we have used a semi-
purified synaptosomal preparation from striatum of mice or rats as a 
reliable in vitro model to study reactive oxygen species (ROS) 
production by these amphetamine derivatives, which is well 
correlated with their dopaminergic injury in in vivo models. Using 
this preparation we have demonstrated that blockade of alpha7 
nicotinic receptors with methyllycaconitine (MLA) and memantine 
(MEM) prevents ROS production induced by MDMA and METH. 
      Studies at molecular level showed that both, MDMA and 
METH, displaced competitively the binding of radioligands for 
homomeric alpha7 and heteromeric nAChRs, indicating that they 
can directly interact with them. In all the cases MDMA displayed 
higher affinity than METH and it was higher for heteromeric than  
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for alpha7 subtype. Preincubation of differentiated PC12 cells with MDMA or METH 
induces nicotinic acetylcholine receptors (nAChR) up-regulation in a concentration- 
and time-dependent manner, as many nicotinic ligands do, supporting their functional 
interaction with nAChRs. Such interaction expands the pharmacological profile of 
amphetamines and can account for some of their effects. 
 
Introduction 
 
 Amphetamine derivatives, such as methamphetamine (METH, speed) and 
3,4-methylenedioxymethamphetamine (MDMA, ecstasy) are widely abused 
drugs, mainly by young people in recreational settings. Besides their 
stimulatory effects, these drugs have been shown to be neurotoxic in animal 
models (for reviews see [1, 2]) in which deleterious effects in dopamine (DA) 
and serotonin (5-HT) nerve terminals have been reported. In addition, signs 
derived from neurotoxicity have been described in humans who are heavy 
users of such drugs [3-6]. The patterns of neurotoxicity of MDMA in mice 
and rats differ in that mice typically exhibit neurotoxicity to both DA- and           
5-HT-containing neurons, whereas rats commonly display selective 
neurotoxicity to 5-HT-containing neurons [7, 8]. 
 Two theories have arisen to explain this neurotoxicity. Firstly, the 
neurotoxicity induced by MDMA may at least partially be a consequence of its 
metabolism [9]. This hypothesis is based on the fact that a direct intracerebral 
injection of MDMA failed to reproduce the neurotoxicity profile that appears 
after its peripheral administration [10]. The other main theory involves reactive 
oxygen species (ROS), although the two theories cannot be considered mutually 
exclusive. Oxidative stress appears to be one of the main factors involved in the 
serotonergic and dopaminergic terminal injury induced by MDMA [11, 12].  
 Although oxidative stress has been proposed as a key neurotoxic 
mechanism induced by these drugs [13, 14], several aspects surrounding the 
concrete pathways involved in METH- and MDMA-induced ROS generation 
remain unresolved. Our research group has recently reported not only that 
METH and MDMA induce ROS production inside rat and mouse striatal 
synaptosomes, but also that endogenous DA is needed for this reaction to 
occur [15-17]. We also determined that methyllycaconitine (MLA), an 
antagonist of α7 nicotinic acetylcholine receptors (α7 nAChR), prevented in 
vitro ROS generation and attenuated in vivo neurotoxicity, thus implicating 
α7 nAChR in the toxicity of amphetamine derivatives.  
 α7 nAChR are homomeric ligand-gated ion channels whose activation 
induces calcium influx. Calcium entry could favour the activation of                 
Ca2+-dependent enzymes such as protein kinase C (PKC) and neuronal nitric 
oxide synthase (nNOS), which have similarly been implicated in the neurotoxicity 
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of amphetamines [18, 19]. In light of these findings, we believed it necessary to 
assess whether METH and MDMA have a direct interaction with α7 nAChR.  
 Certain previous reports have suggested that amphetamines interact with 
different nicotinic receptors. Liu et al. [20] reported that D-amphetamine acts 
as an agonist on nicotinic receptors (probably α7) in bovine chromaffin cells, 
inducing catecholamine release. In addition, Skau and Gerald (1978) [21] had 
reported that D-amphetamine inhibits α-bungarotoxin binding at the 
neuromuscular junction in mice, while Klingler et al. [22] recently identified 
nAChR as one of the physiological targets of MDMA in the neuromuscular 
junction. Our previous findings [15-17] relate such an interaction to 
neurotoxicity. Moreover, as it has been extensively reported that chronic 
treatment with nicotine and nicotinic ligands induces an up-regulation of 
nicotinic receptors in central nervous system (CNS) [23, 24], the effect of 
amphetamines on nicotinic receptor populations warrants further study.  
 We demonstrated, using radioligand binding assays, the interaction of 
METH and MDMA with homomeric α7 nAChR and heteromeric subtypes of 
nicotinic receptors, such as α4β2. We previously demonstrated in vitro that 
Ca2+ chelation with EGTA prevented ROS production to a similar extent as 
nAChR blockade [12, 15-17]. This indicates that calcium influx, probably 
through α7 nAChR, is a key step in this process. Consequently, one of the 
objectives of the final work was to use a fluorimetric method to investigate the 
effect of MDMA on Ca2+ levels in cultured PC12 cells and the involvement of 
different nAChR subtypes and other cell pathways related to Ca2+ mobilization. 
In addition, we investigated the effects of pretreatment with METH and 
MDMA on nAChR densities.  
 PC12 cells have been utilized by other scientists to study the 
neurotoxicity of amphetamines [25-27]. In addition, this cell line expresses 
nAChRs, including the α7 subtype [28-30], and also provides an in vitro 
model for the up-regulation of nAChR, which occurs following chronic 
exposure to nicotine [31, 32]. Moreover, the pathways involved in cytosolic 
Ca2+ increase induced by different selective nicotinic agonists have been 
characterized in this cell line [33]. For this reason, we chose this model and 
the isolated synaptosomes as the most appropriate for our purposes. 
 Herein we present the most important points brought out by our research. 
 
1. DA, PKC and nNOS involvement in METH- and MDMA-induced 
ROS production  
 
 Our study was undertaken with the goal of developing an alternative in 
vitro model that might be useful for studying the molecular mechanisms of 
METH-induced DA neurotoxicity. With this purpose we used the fast and 
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simple method for isolating synaptosomes described by Myhre and Fonnum 
[34]. Using this model the formation of intrasynaptosomal ROS was measured 
using the conversion of the non fluorescent 2’,7’– dichlorofluorescein 
diacetate (DCFH-DA) to the highly fluorescent compound 2’,7’-
dichlorfluorescein (DCF). 
 METH increases DCF fluorescence when added to our preparation, which 
indicates that it induces ROS production [15]. Incubation of synaptosomes with 
METH for a few minutes also causes release of DA from presynaptic nerve 
terminals and inhibits DA uptake, probably by reversion of dopamine 
transporter (DAT) functionality. When we used synaptosomes from                    
DA-depleted rats (pretreated with reserpine or reserpine plus alpha-methyl-p-
tyrosine) the METH-induced ROS production was inhibited, thus corroborating 
DA as the main source of ROS detected (Fig. 1). Besides, METH, by altering 
the intracellular pH gradient, prevents vesicular monoamine transporter 
(VMAT) function and promotes DA release from vesicles to cytosol [35] where 
it can be oxidized. By this way, in vitro incubation of synaptosomes with 
substances that block VMAT (reserpine) prevents METH oxidative effect. 
  
 
 
Figure 1. Effect of catecholamine depletion on METH-induced ROS in rat striatal 
synaptosomes. Rats were pretreated with saline (normal), reserpine (RES), or with 
reserpine plus alpha-methyl-p-tyrosine (RES + AMPT). Synaptosomes were obtained, 
and incubated alone (CTRL) or with 2 mM METH. *P<0.05 versus normal control 
group. Results are mean ± S.E.M. of at least three separate experiments run by 
triplicate. Differences between groups were compared using one-way analysis of 
variance (ANOVA, two-tailed). Significant (p < 0.05) differences were then analyzed 
by Tukey’s post hoc test for multiple means comparisons where appropriate.  
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 Activation of nNOS produces NO, which reacts with the peroxide radicals 
which would originate from DA autooxidation, producing the more toxic 
radical peroxynitrite (ONOO−). In our model, the inhibitor of nNOS, 7-NI, 
completely abolished METH-induced ROS production, demonstrating a role 
of the enzyme nNOS in METH oxidative effects. 
 PKC has been implicated in various aspects of DAT function and its 
direct phosphorylation [36]. In our model, inhibition of PKC (by NPC               
15437, 2,6-diamino-N-[[1-(1-oxotridecyl)-2-piperidinyl]methyl]hexanamide 
dihydrochloride) fully prevented METH-induced ROS, corroborating a key 
role of PKC in this process. 
 Therefore an increase in cytosolic DA and activation of nNOS and PKC 
(blocking DA transport through DAT) are needed to generate ROS inside the 
dopaminergic terminal. Both, PKC and nNOS are enzymes that require 
calcium to be activated. Accordingly, when calcium of the medium was 
chelated with EGTA, the oxidative effect of METH was prevented. 
 Also MDMA induces oxidative stress [12]. The MDMA concentration-
response curve showed an inverted “U” shape and the maximal oxidative 
effect appeared at 50-100 μM and showed the same dependences. 
 
2. nAChR involvement in METH and MDMA-induced ROS 
production  
 
 Ionotropic homomeric nicotinic receptors made of five alpha7 subunits are 
permeant to Na+ and Ca2+. Although alpha7 neuronal nicotinic receptors are a 
minority type in the striatum, they are expressed on DA axon terminals [37]. For 
this reason we tested the involvement of nicotinic alpha7 receptors in our 
preparation, using the specific antagonist MLA. MLA completely inhibited 
METH and MDMA-induced ROS production, as well as alpha-bungarotoxin 
(another prototypic alpha7 antagonist) while dihydro-beta-erythroidine (DBE), 
an antagonist that blocks receptors containing beta2 subunits was devoid of 
effect, thus implicating alpha7 receptors [15]. On the basis of these antecedents, 
we considered the possibility that MDMA might also exert an oxidative effect 
dependent on nAChR stimulation. Specific beta2-subunit-containing and alpha7 
nAChR antagonists fully inhibited the oxidative stress induced by MDMA. 
 Additionally, MLA inhibited the remaining effect of MDMA in the 
presence of catalase plus superoxide dismutase (attributed to NO), pointing a 
role of alpha7 nAChR in the activation of nNOS induced by MDMA. 
 
2a. In vivo MLA protects from METH- and MDMA-induced dopaminergic 
neurotoxicity 
 
 Assessment of neurotoxicity markers after an in vivo treatment               
with a neurotoxic schedule of METH or MDMA was used to determine the  
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Figure 2. Panel A. Effect of in vivo treatment with MDMA (three injections, 25 mg/kg 
s.c., 3-h intervals) or in combination with MLA (three injections, 6 mg/kg i.p., 20 min 
before MDMA) on the density of mouse striatal dopamine reuptake sites at 7 days after 
treatment, and measured as specific binding of [3H]WIN 35428. ** P< 0.01 vs saline-
treated group. Panel B: Effect of treatment with MDMA alone or in combination with 
MLA (same dose schedule as above) on the density of mouse striatal serotonin 
reuptake sites 7 days after treatment, measured as specific binding of [3H] paroxetine. 
**P<0.01, *** P<0.001 vs saline-treated group; #P< 0.05 vs MDMA-treated group. In 
both panels values are expressed as means ± S.E.M. of those obtained from 5 - 6 
animals in each group. One-way ANOVA and Tukey's post hoc test. 
 
neuroprotective effect of MLA (administered 20 min before each dose of 
METH or MDMA) in mice [16, 17].  
 METH induced, at 72 h post-treatment, a significant loss of striatal DA 
reuptake sites of about 73%, measured as specific binding of [3H]WIN 35428 
((–)-2- β-carbomethoxy-3-β-(4-fluorophenyl)tropane) in mouse striatum 
membranes. This dopaminergic injury was attenuated in mice pretreated with 
MLA (from 73% to 43%).  
Amphetamines and nicotinic receptors 161 
 The in vivo neurotoxic model of MDMA used was characterized by a 
significant loss of DA terminals (69%) and a decrease of tyrosine hydroxylase 
levels (65%) in striatum from mice sacrificed 7 days post-treatment. This 
terminal loss was prevented by pretreatment with MLA, pointing also to a 
neuroprotective effect against this amphetamine derivative. 
 [3H]Paroxetine binding, which labels SERT, was measured also in the 
hippocampus of these animals, as a marker of degeneration of serotonin 
terminals. Conversely, MLA did not prevent the loss in [3H]paroxetine binding 
sites, indicating that its neuroprotective effect is selective for DA terminals. 
 
2b. Memantine protects from MDMA-induced CNS injury 
 
 Memantine (MEM), a non-competitive antagonist of the NMDA receptor, 
is a drug used to treat moderate-to-severe Alzheimer’s disease. It reduces 
tonic [38] but not synaptic, NMDA receptor activity. 
 In 2005, the group of Aracava demonstrated that MEM, at clinically 
relevant concentrations, can block alpha7 nAChR in a non-competitive 
manner, and more effectively that it does at NMDA receptors [38]. 
 Our in vitro neurotoxicity studies showed that MEM had not antioxidant 
effect versus H2O2 but inhibited the ROS production induced by MDMA at all 
the concentrations tested. The oxidative effect of amphetamine derivative was 
reinforced by PNU 282987 an alpha7 specific agonist. 
 In vivo experiments were carried out with Dark Agouti rats, that are more 
sensitive to low doses of drugs, and we used it as a model of serotonergic 
neurotoxicity induced by MDMA. A significant decrease in the SERT density 
was observed in both, the hippocampus and frontal cortex of MDMA-treated 
Dark Agouti rats sacrificed 1 or 7 days post-treatment. In both cases, MEM 
significantly prevented the loss of [3H]paroxetine binding sites, suggesting a 
neuroprotective effect on serotonin terminals [39] (Table 1).  
 
Table 1. Effect of memantine in the abundance of 5-HT (rat hippocampus) transporters 
(labeled by [3H]paroxetine), and also in the glial activation measured by the 
[3H]PK11195 binding in those tissues in rats killed 7 days post-treatment. 
 
 
 
 
 
Results are expressed as mean ± S.E.M. from 6-9 different experiments. * P<0.05 
and ** P<0.01 vs Saline; # P<0.05 and ### P<0.001 vs. MDMA group. 
Treatment [3H]Paroxetine             
binding (%) 
[3H]PK 11195  
binding (%) 
Saline 100.00 ± 9.34 100.00 ± 6.35 
MDMA 70.02 ± 7.85 * 168.22 ± 20.65 ** 
MEM 116.40 ± 3.95 94.90 ± 7.05 
MDMA + MEM 94.87 ± 4.96 104.41 ± 9.77 # 
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 Accordingly with our results, MEM could be used not only to treat these 
addictions or to prevent the effects of these amphetamine derivatives, but it 
may also have a beneficial effect on the memory impairment that abusers of 
these drugs usually suffer [40]. 
 
3. Nicotinic receptors and the cognitive impairment induced by 
MDMA 
 
 In our laboratory we performed some experiments to demonstrate a 
specific effect of MDMA treatment on the object recognition memory test and 
the Morris water maze in Long Evans rats [41]. Animals pre-treated with 
MEM did not exhibit the lack of memory that appeared in the MDMA-treated 
animals. Therefore, MEM by preventing MDMA-induced neuronal injury 
contributes to ameliorate cognitive impairment produced by MDMA, this 
preventive effect on MDMA-induced impairment suggesting a new 
therapeutic approach to the treatment of long-term adverse effects of 
amphetamine derivatives. 
 
4. Amphetamine derivates directly interact with nAChR 
 
 METH and MDMA displaced both [3H]epibatidine ([3H]EB) and [3H]MLA 
binding in PC12 cells and mouse brain, indicating that they can directly 
interact with nAChR. MDMA displayed higher affinity than METH for both 
subtypes of nAChR. The resulting Ki values fell in the micromolar range, 
although some of them are in the low micromolar range and other in the high 
micromolar range (Table 2). 
 Special attention must be paid in the affinity for heteromeric receptors (Ki 
about 0.7 µM) which is practically the same that the Ki displayed by MDMA 
for the serotonin transporter, its main physiological target (0.61 µM) [42]. 
Therefore an interaction of MDMA on heteromeric nAChR at recreational doses 
 
Table 2. Ki values of METH and MDMA against [3H]MLA and [3H]EB binding in 
mouse brain. 
 
 [3H]EB [3H]MLA 
Drugs Ki (μM) nH Ki (μM) nH 
METH 23.90 ± 2.65 1.27 ± 0.28 369.77 ± 95.61 0.29 ± 0.08* 
MDMA 0.76 ± 0.11 0.83 ± 0.12 34.21 ± 6.71 0.40 ± 0.27* 
 
 
The Ki values from competition binding curves were calculated using the Cheng–Prusoff 
equation.* Significantly different from 1 (one sample t-test).  Results are expressed as 
mean ± S.E.M. from 4-6 different experiments. 
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is certainly possible. The fact that the lowest Ki values were found against 
[3H]epibatidine binding indicates that METH and MDMA displayed higher 
affinity for heteromeric nAChR which are the most abundant in the CNS. 
 We also performed binding experiments with MDMA enantiomers in 
order to determine a difference between (R)-MDMA and (S)-MDMA in their 
capability of displacing [3H]EB and [3H]MLA from their binding sites. When 
[3H]EB was used as a radioligand to label α4β2 nAChR, (R)-MDMA and           
(S)-MDMA induced a concentration-dependent binding displacement, with 
IC50 values in the micromolar range (see Table 3). The affinity of (R)-MDMA 
for [3H]EB binding sites was higher than (S)-MDMA. The Hill coefficients 
resulting from the analysis of competition data of MDMA vs [3H]EB were not 
significantly different from unity, pointing to a competitive displacement. 
 When [3H]MLA was used as a radioligand to label α7 nAChR,  no 
differences between (R)-MDMA and (S)-MDMA were found. The Ki values 
were similar for both enantiomers.  
  
Table 3. Ki values of (R)- and (S)-MDMA against [3H]MLA and [3H]EB binding to rat 
membranes. 
 
 
 
 
 
The Ki values from competition binding curves were calculated using the Cheng–Prusoff 
equation. .* Significantly different from 1 (one sample t-test). . Results are expressed as 
mean ± S.E.M. from 3-4 different experiments. 
 
5. METH and MDMA increase the density of nicotinic receptors 
 
 A particular feature of nAChR is that chronic exposure to nicotine 
induces a higher level of either nicotine or epibatidine binding, termed as up-
regulation [43]. Accordingly, we tested whether METH and MDMA had any 
effect on α7 and heteromeric nAChR binding densities and found that both 
were increased in a time- and concentration- dependent manner (Fig. 3). 
 The mechanism through which nicotine induces nAChR up-regulation is 
complex and not fully clarified to date (reviewed by Gaimarri et al. [44]). 
There are reports indicating that nicotine-induced increases in nAChR are not 
accompained by changes in mRNA encoding for the different subunits               
[45, 46]. This led to other hypotheses, such as reduced receptor turnover, 
promotion of the assembly and migration to the plasma membrane of pre- existing 
Radioligand  Ligand IC50 ± SEM (μM) Ki ± SEM (μM)      nH 
[3H]EB (R)-MDMA  0.37 ± 0.0 0.6 ± 0.2 1.0 ± 0.0 
[3H]EB (S)-MDMA  9.7 ± 1.0 8.2 ± 2.0 0.8 ± 0.1 
[3H]MLA (R)-MDMA 149.3 ± 22 71.8 ± 10 0.6 ± 0.1* 
[3H]MLA (S)-MDMA  131 ± 27 63.1 ± 17 0.5 ± 0.3* 
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Figure 3. Time-course study of the increases in [3H]MLA (panel A) and 
[3H]epibatidine (panel B) binding sites induced by METH and MDMA (300 μM). 
PC12 cells were incubated with amphetamine derivatives over 6, 24 and 48 h. 
Thereafter radioligand binding was performed on intact cells in culture. Data represent 
the means ± S.E.M. of three separate experiments carried out in triplicates (*P < 0.05, 
** < 0.01, ***P < 0.001 vs. untreated cells; #P < 0.05, ##P < 0.01, ###P < 0.001 vs. 
METH at the same incubation time). 
 
intracellular subunits [29] or decrease in the rate of receptor turnover [47]. 
More recently, Sallette et al. [48] demonstrated that nicotine acts as a 
maturation enhancer of those intracellular nAChR precursors that would 
otherwise be degraded. However, different authors show controversial results. 
Vallejo et al. [49] reported that α4β2 up-regulation by nicotine is due to an 
increase/stabilisation of the proportion of receptors in a high affinity state and 
not to an enhancement in receptor maduration.  
 Regardless the underlying mechanism, according to our competition 
experiments demonstrating the affinity of METH and MDMA for nAChR, it 
could be hypothesised that the up-regulation of nAChR induced by these 
drugs would follow a similar mechanism.  
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6. Role of protein synthesis, cyclophilin A, protein kinase and 
receptor trafficking 
 
 The protein synthesis inhibitor cycloheximide (CHX) inhibited the 
increase in both [3H]MLA and [3H]epibatidine binding sites, suggesting that 
such up-regulation require, at least in part, rapid protein synthesis. The 
chaperone cyclophilin A participates in α7-nAChR maturation [29, 50]. 
Therefore we tested the cyclophilin A inhibitor cyclosporin A (CsA) on 
METH/MDMA-induced nAChR up-regulation. CsA inhibited 
METH/MDMA-induced up-regulation. 
 To assess whether receptor trafficking to the plasma membrane could be 
contributing to METH/MDMA-induced nAChR up-regulation we exposed the 
cells to BFA to inhibit such transport and late steps of maturation. Although 
BFA induced dramatic decreases in basal binding sites owing to its main 
mode of action, there was still up-regulation after treatment with 
METH/MDMA. This indicates that trafficking is not crucial for 
METH/MDMA-induced nAChR up-regulation and that this takes place 
previously to surface expression. This result is in agreement with those 
reported in other studies on the mechanisms involved in nicotine-induced          
up-regulation of heteromeric receptor [49,51]. 
 PKA- and PKC-dependent pathways have been found to play a role in the 
up-regulation of α4β2 receptors induced by cholinergic ligands in several cell 
lines [52, 53]. For this reason we tested the PKA inhibitor H-89 on 
METH/MDMA-induced up-regulation. We saw that there was an inhibition 
by H-89, corroborating that PKA plays a role in heteromeric nAChR 
regulation, but not in that of α7 nAChR [53]. The PKC inhibitor,               
GF-109203X, did not affect α7 nAChR in our experiments with amphetamine 
derivatives. This result is in agreement with those reported by Nuutinen et al. 
[53] who found no effect of this compound, at nanomolar concentration, on 
nicotine-induced α7 nAChR up-regulation.  
 Protein tyrosine kinases have been reported to play a role in α7 nAChR 
regulation [54,55]. When genistein, an inhibitor of tyrosine kinases, was assayed 
for 24 h, it reduced METH/MDMA effects on nAChR densities, indicating that 
they participate in the up-regulation induced by METH and MDMA. 
 All these results confirm that METH and MDMA up-regulate nAChR in a 
complex process but in a similar manner than nicotine. However, the work 
done to date indicates that up-regulation can occur if the drug has a particular 
affinity to one or more nAChR subunits; regardless of the agonist/antagonist 
properties of the drug (i.e., the antagonist DHβE is also able to induce it [52]. 
In addition, up-regulation is enhanced when the drug crosses the cell 
membrane to interact with immature forms of the receptor [56]. The affinity 
of MDMA towards both heteromeric and α7 nAChRs has been demonstrated 
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[30], and this drug can reach the cytosplasm after transport through the 
dopamine transporter [57, 58], which is abundant in PC12 cells. Therefore, the 
interaction of MDMA with immature receptor subunits is feasible.  
 
7. Intracellular Ca2+ increase induced by MDMA in PC12 cells 
 
 We used a fluorimetric method [33] to investigate the effect of MDMA on 
Ca2+ levels in cultured PC12 cells and the involvement of different nAChR 
subtypes and other cell pathways related to Ca2+ mobilization.  
 MDMA acutely inhibited the effects of nAChR agonists (ACh, Nic and 
PNU282987) (Fig. 4a) but, owing to its effects increasing basal calcium levels  
 
 
 
Figure 4. (Panel A) Effect of increasing concentrations of MDMA on the responses to 
the nicotinic agonists ACh (100 μM), nicotine (100 μM), and PNU 282987 (0.1 μM) in 
PC12 cells loaded with Fluo-4. MDMA was added to the cells 5 min before the 
agonist. Basal fluorescence levels were measured for 5 s before the agonist and for a 
further 30 s after its addition by means of an automated injector. (Panel B) Basal Ca2+ 
levels 5 min after the addition of MDMA and before adding the agonist. All the 
measurements were performed in the presence of the positive allosteric modulator 
PNU 120596 (10 μM). The results were normalized as percentage (Fmax − Fmin) and are 
the means ± SEM of at least three experiments, carried out in quadruplicates for each 
condition. ** P < 0.01, *** P < 0.001 vs. control basal levels. 
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(Fig. 4b), we explored the possibility of a partial agonist mode of action. We 
tested the effect of acute application of MDMA and found a concentration-
effect relationship in the micromolar concentration range. The effect of 
MDMA did not reach the maximum values induced by ACh, which indicates 
a partial agonist mode of action (Fig. 5). The EC50 value was in the 
micromolar range, which is in agreement with previous binding results.  
 The experiments performed with MDMA enantiomers demonstrated that 
there are no differences in the calcium increase between the enantiomers and 
the racemic mixture. This results is in agreement with the similar affinity 
values obtained of both enantiomers in the binding experiments with 
[3H]MLA. 
 
 
 
Figure 5. (Panel A) Representative tracings of the increases in Fluo-4 fluorescence in 
PC12 cells after the addition (arrow) of ACh (1 μM) and MDMA (50 μM). (Panel B) 
Representative concentration–response curves showing the increase in cytosolic Ca2+ 
induced by MDMA and ACh as a total agonist. Responses were normalized as 
percentage (Fmax − Fmin) and represented as a percentage of the maximum response 
(ACh 100 μM) for both curves. After 5 s of basal recording, ACh and MDMA were 
added by means of an automated injector to PC12 cells loaded with Fluo-4 and the 
fluorescence was measured for a further 30 s. Represented data are the mean ± SEM of 
four replicates for each condition. 
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8. Pathways involved in MDMA-induced Ca2+ increase 
 
 The fact that MDMA induced an increase in cytosolic Ca2+ led us to study 
the pathways involved using specific blockers (Fig. 6). According to our 
previous work, the α7 nAChR blockers MLA and α-bungarotoxine (α-BgTX) 
abolished the effect of MDMA, which showed that such effects take place 
mainly through activation of these receptors. However, as we had previously 
described that MDMA also has affinity for heteromeric receptors [12, 30], we 
tested the effect of DBE, an antagonist of these receptors, and we found that it 
had no significant effect on MDMA-induced Ca2+ increase, ruling out an 
antagonistic effect on theses receptors. This finding suggests that MDMA 
behaves as an antagonist at heteromeric receptors while it is a partial agonist 
at α7 nAChRs. These receptors are permeant to Na+, which could induce 
depolarization and open voltage-operated calcium channels (VOCC) [33].            
We used nitrendipine, an L-type VOCC inhibitor, and Cd2+, a non selective  
 
 
 
Figure 6. Pharmacological modulation of MDMA-induced increase in cytosolic Ca2+. 
Drugs were manually added to cultured PC12 cells loaded with Fluo-4, 10 min before 
the automated addition of MDMA (50 μM). The response was measured for 5 s before 
and 30 s after MDMA, then normalized as percentage (Fmax − Fmin) and expressed as a 
percentage of the response induced by MDMA alone. All the measurements were 
carried out in the presence of PNU 120596 (10 μM). Abbreviations and concentrations 
used: MLA (methyllycaconitine, 1 μM), DHβE (dihydro-β-erythroidine, 50 μM), 
DANT (dantrolene, 20 μM), 2-APB (2-aminoethyl diphenyl borate, 150 μM), NDP 
(nitrendipine, 30 μM), ATR (atropine, 0.1 μM). Results are mean ± SEM of three 
experiments carried out in quadruplicates. *P < 0.05,** P < 0.01,*** P < 0.001 vs. 
MDMA alone. 
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blocker of VOCC and found that they inhibited MDMA-induced Ca2+ 
suggesting that, in our model, the initial depolarization induced after α7 
receptor activation by MDMA, partially couples to L-type channel opening. 
 Calcium-induced calcium release (CICR) from endoplasmic reticulum 
(ER) stores has been shown to be coupled to a α7 nAChR activation [33, 59]. 
CICR could occur after activation of two intracellullar calcium release 
channels localized in the ER: IP3 receptors and ryanodine receptors [60, 61]. 
Accordingly we tested two blockers of these receptors (2-APB and dantrolene, 
respectively) with MDMA. We found that the MDMA effect was significantly 
inhibited by these blockers, which demonstrates the participation of CICR. In 
fact, these blockers had also been effective in preventing MDMA-induced 
ROS generation in striatal synaptosomes [62].   
 The MDMA response was dependent on extracellular Ca2+, as 
suppression of this cation totally inhibited its effect. Extracellular Ca2+ could 
enter through either α7 channels or L-type VOCCs and, as stated above, this 
Ca2+ increase would also induce subsequent CICR. 
 Although mechanisms other than nAChR activation cannot be totally 
ruled out in the MDMA-induced increase in cytosolic Ca2+, the practically 
complete inhibition by MLA and α-BgTX indicates that α7 nAChR activation 
plays a major role in this process.  
 
9. Effects of MDMA on basal Ca2+ levels 
 
 Preincubation with MDMA for 24 h induced an increase in basal 
cytosolic Ca2+ levels, as measured after drug washout. Surprisingly, 
preincubation with nicotine increased basal levels when it was carried out for 
1 h, but not after longer preincubation times. This indicates that cells are able 
to buffer sustained activation by nicotine, but not that induced by MDMA, 
which suggests increased vulnerability to this drug. 
 
10. Calpain/Caspase-3 activation induced by MDMA 
 
 Sustained Ca2+ influx after MDMA treatment could favor cytotoxicity 
through activation of Ca2+-dependent pathways (i.e., calpain). Calpain is a 
calcium-dependent protease whose activation is a primary mechanism that 
contributes to several types of neurodegenerative conditions, including the 
excitatory amino acid-induced neurotoxicity that is associated with traumatic 
brain injury, ischemia, and hyperthermia [63,64]. Calpain specifically 
degrades the cytoskeletal membrane protein, spectrin, into 145 and 150 kDa 
breakdown products [65]. Caspase 3 is another cysteine protease that is 
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involved in apoptotic pathways. It also degrades spectrin but produces a 120 kDa 
spectrin fragment [66] and also can produce a 150-kDa fragment [67].  
 Incubation of PC12 cells with MDMA for 24 h induced a significant 
increase in α-spectrin breakdown products (SBDP) of 145 and 150 kDa, 
which indicates calpain activation, and a rise in the 120 kDa band that, 
together with the increase in the 150 kDa SBDP, points to caspase 3 activation 
(Fig. 7). In fact, in a previous work using cerebellar granule cells, we 
demonstrated the proapoptotic role of caspase 3 in the neurotoxic effects of 
amphetamines [68]. Moreover, the increases in SBDP induced by MDMA 
were prevented by MLA, indicating that α7 nAChRs play a key role in this 
process.  
 
 
 
Figure 7. (Panel A) Representative Western blot of α-spectrin breakdown products 
(SBDP) originated by calpain activation (145 and 150 kDa) and caspase 3 (120 and 
150 kDa) after 24-h treatment with culture medium (Ctrl), MDMA (50 μM), 
MDMA + MLA (10 nM), and MLA alone. The localization of the molecular weight 
(MW) markers is shown on the left of the picture. (Panel B) Quantification of dot 
intensity of the SBDPs. Data are the means ± SEM of three different cultures, loaded 
in duplicates. *P < 0.05 and **P < 0.001 vs. control. 
 
11. Functional up-regulation 
 
 After chronic nicotine exposure, some nAChR subtypes undergo 
radioligand binding up-regulation, changes in stoichiometry, and an increase 
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in functional state (functional up-regulation) (reviewed in [44]). Such               
up-regulation occurs at a post-transcriptional level and has been reported in 
cell cultures for α4β2 nAChRs [56,69] as well as for α7 nAChRs [70]. For this 
reason, we measured cytosolic Ca2+ levels to test whether pretreatment with 
MDMA induced persistent changes in nAChRs, leading to an increased 
response to agonists. Our experiments showed that, when incubated for 24 h 
with MDMA, PC12 cells exhibited increased responses to PNU282987               
(N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-4-chlorobenzamide) (α7-selective) and to 
5-I-A-85380 (3-[(2S)-2-azetidinylmethoxy]-5-iodopyridine dihydrochloride) 
(selective for β2 subunit-containing receptors), measured after drug washout. 
This indicates that MDMA also induces functional nAChR up-regulation.  
 
12. Final remarks 
 
 Our work demonstrates an additional mode of action for amphetamine 
derivatives. Their activation of α7 nAChR contributes to the toxicity of these 
drugs, which points to a new target to reduce damage. Moreover, the effects 
on different nAChR densities may account for long term effects on neural 
pathways and addiction processes due the important role of these receptors in 
CNS functions. 
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